Physician profile
Mark Lantz
NPI 1295909398
$1,648.09
in general payments reported to CMS, 2019-2025
16 companies · $479 in 2025
The $479 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $168 · 2021: $49.06 · 2022: $212 · 2023: $20.58 · 2024: $314 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $813.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $330.09 | 2025 | |
| Alcon Vision LLC | $282.07 | 2019-2024 | Clareon |
| Coopervision INC. | $161.03 | 2020-2025 | Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $152.25 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $151.61 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $127.96 | 2024-2025 | |
| Abbvie INC. | $112.09 | 2024-2025 | |
| Oyster Point Pharma, INC. | $82.99 | 2022-2024 | Tyrvaya, Ryzumvi |
| Lombart Brothers, INC. | $71.92 | 2019 | |
| Bausch & Lomb Americas INC. | $62.79 | 2024-2025 | Xiidra, Miebo, Infuse |
| Astellas Pharma US INC | $30.40 | 2024 | Izervay |
| Mallinckrodt Hospital Products INC. | $21.72 | 2025 | Acthar |
| Optos, INC. | $18.21 | 2021 | |
| Aerie Pharmaceuticals, INC. | $15.78 | 2021 | |
| Dompe US, INC. | $15.07 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.